TY - JOUR
T1 - Synaptic Terminal Density Early in the Course of Schizophrenia
T2 - An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A
AU - Onwordi, Ellis Chika
AU - Whitehurst, Thomas
AU - Shatalina, Ekaterina
AU - Mansur, Ayla
AU - Arumuham, Atheeshaan
AU - Osugo, Martin
AU - Marques, Tiago Reis
AU - Jauhar, Sameer
AU - Gupta, Susham
AU - Mehrotra, Ravi
AU - Rabiner, Eugenii A.
AU - Gunn, Roger N.
AU - Natesan, Sridhar
AU - Howes, Oliver D.
N1 - Funding Information:
For the purpose of open access, this paper has been published under a creative common license (CC-BY) to any accepted author manuscript version arising from this submission. This study was funded by Medical Research Council-UK (Grant Nos. MC_U120097115 , MR/W005557/1 , and MR/V013734/1 [to ODH]) and Wellcome Trust (Grant No. 094849/Z/10/Z [to ODH]) and by the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. ECO acknowledges support from the National Institute for Health Research . The views expressed are those of the authors and not necessarily those of the National Health Service/National Institute for Health Research or the Department of Health.
Funding Information:
EAR and RNG are employees of Invicro LLC. AM was an employee of Invicro LLC during the completion of much of this work. RNG is a consultant for AbbVie, Biogen, and Cerveau. TRM has received honoraria for speaking and chairing from Lundbeck, Janssen, and Astellas and received honoraria to participate in advisory boards organized by Angelini Pharmaceuticals. In the last 3 years, SJ has given nonpromotional educational talks for Lundbeck, Janssen, and Sunovion. ODH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche, and Viatris/Mylan. ODH has a patent for the use of dopaminergic imaging. The other authors report no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2023 Society of Biological Psychiatry
PY - 2024/4/1
Y1 - 2024/4/1
N2 - Background: The synaptic hypothesis is an influential theory of the pathoetiology of schizophrenia (SCZ), which is supported by the finding that there is lower uptake of the synaptic terminal density marker [11C]UCB-J in patients with chronic SCZ than in control participants. However, it is unclear whether these differences are present early in the illness. To address this, we investigated [11C]UCB-J volume of distribution (VT) in antipsychotic-naïve/free patients with SCZ who were recruited from first-episode services compared with healthy volunteers. Methods: Forty-two volunteers (SCZ n = 21, healthy volunteers n = 21) underwent [11C]UCB-J positron emission tomography to index [11C]UCB-J VT and distribution volume ratio in the anterior cingulate, frontal, and dorsolateral prefrontal cortices; the temporal, parietal and occipital lobes; and the hippocampus, thalamus, and amygdala. Symptom severity was assessed in the SCZ group using the Positive and Negative Syndrome Scale. Results: We found no significant effects of group on [11C]UCB-J VT or distribution volume ratio in most regions of interest (effect sizes from d = 0.0–0.7, p >.05), with two exceptions: we found lower distribution volume ratio in the temporal lobe (d = 0.7, uncorrected p <.05) and lower VT/fp in the anterior cingulate cortex in patients (d = 0.7, uncorrected p <.05). The Positive and Negative Syndrome Scale total score was negatively associated with [11C]UCB-J VT in the hippocampus in the SCZ group (r = −0.48, p =.03). Conclusions: These findings indicate that large differences in synaptic terminal density are not present early in SCZ, although there may be more subtle effects. When taken together with previous evidence of lower [11C]UCB-J VT in patients with chronic illness, this may indicate synaptic density changes during the course of SCZ.
AB - Background: The synaptic hypothesis is an influential theory of the pathoetiology of schizophrenia (SCZ), which is supported by the finding that there is lower uptake of the synaptic terminal density marker [11C]UCB-J in patients with chronic SCZ than in control participants. However, it is unclear whether these differences are present early in the illness. To address this, we investigated [11C]UCB-J volume of distribution (VT) in antipsychotic-naïve/free patients with SCZ who were recruited from first-episode services compared with healthy volunteers. Methods: Forty-two volunteers (SCZ n = 21, healthy volunteers n = 21) underwent [11C]UCB-J positron emission tomography to index [11C]UCB-J VT and distribution volume ratio in the anterior cingulate, frontal, and dorsolateral prefrontal cortices; the temporal, parietal and occipital lobes; and the hippocampus, thalamus, and amygdala. Symptom severity was assessed in the SCZ group using the Positive and Negative Syndrome Scale. Results: We found no significant effects of group on [11C]UCB-J VT or distribution volume ratio in most regions of interest (effect sizes from d = 0.0–0.7, p >.05), with two exceptions: we found lower distribution volume ratio in the temporal lobe (d = 0.7, uncorrected p <.05) and lower VT/fp in the anterior cingulate cortex in patients (d = 0.7, uncorrected p <.05). The Positive and Negative Syndrome Scale total score was negatively associated with [11C]UCB-J VT in the hippocampus in the SCZ group (r = −0.48, p =.03). Conclusions: These findings indicate that large differences in synaptic terminal density are not present early in SCZ, although there may be more subtle effects. When taken together with previous evidence of lower [11C]UCB-J VT in patients with chronic illness, this may indicate synaptic density changes during the course of SCZ.
KW - Antipsychotic-free
KW - Positron emission tomography
KW - Schizophrenia
KW - SV2A
KW - Synaptic density
KW - UCB-J
UR - http://www.scopus.com/inward/record.url?scp=85169460609&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2023.05.022
DO - 10.1016/j.biopsych.2023.05.022
M3 - Article
C2 - 37330164
AN - SCOPUS:85169460609
SN - 0006-3223
VL - 95
SP - 639
EP - 646
JO - Biological psychiatry
JF - Biological psychiatry
IS - 7
ER -